30 closest matches · ranked by relevance
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
Arteriovenous Fistula Stenosis
Primary: Primary Safety Endpoint: Serious Adverse Event Rate — 0; 2.7 percentage of patients
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
AV Fistula
Primary: Time to AV Fistula Functional Maturation — 169; 145 Days to functional maturation
Chronic Kidney Disease
Primary: Venous Diameter. — 5.78; 6.42 mm
Complication of Renal Dialysis · End Stage Renal Disease · End Stage Kidney Disease
Primary: Fistula Suitability for Dialysis at 6 Months (FSD6) — 74; 76; 21; 43 Participants — p=0.2942
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
Chronic Kidney Disease
Primary: Time to AVF Primary Unassisted Patency — 214; 171 Days — p=0.254
Kidney Diseases · Arteriovenous Fistula
Primary: Primary Safety Endpoint — 0 MAES within 30 days post baseline visit
Chronic Kidney Disease
Primary: Kaplan-Meier Estimate of Secondary AVF Patency — NA; NA Days — p=0.932
End Stage Renal Disease · AV Fistula · Kidney Failure
Primary: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis — 49 participants
Arteriovenous Fistula
Primary: Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure — 71.4; 63 Percentage of Participants — p=0.0562
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Arteriovenous Fistulae
Primary: Number of Participants With Fistula Failure — 11; 15 Participants
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
Vascular Access Complications · Cardiac Catheterization · Peripheral Vascular Disease
Primary: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography — 408; 431 participants
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Hemodialysis Access Failure
Primary: Number of Participants With Target Lesion Primary Patency at 6 Months Post Procedure — 11 Participants
Arteriovenous Fistula, Cannulation
Primary: Infiltration Due to Dialysis Access Cannulation — 5; 7 infiltration events
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
Stenoses
Primary: Percent of Participants With Treatment Area Primary Patency (TAPP) — 51; 23; 60 Percentage of Participants — p=<0.001
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Primary: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application. — 62.9; 31.4 Percentage of participants — p=<0.0001
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…